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Detection of human parvovirus B19 in cases
of hydrops fetalis in São Paulo, Brazil
Detecção de parvovírus humano B19 em casos de hydropsia fetal em São Paulo, Brasil
Cristina Adelaide Figueiredo1; Maria Isabel de Oliveira2; Ana Maria Sardinha Afonso3; Joelma Queiroz Andrade4; Maria de Lourdes 
Brizot5; Marcelo Zugaib6; Suely Pires Curti7
Human parvovirus B19 infection is known to be one of the causes of hydrops fetalis. The maternal 
infection caused by the virus may be symptomatic or asymptomatic. In this study, 40 pregnant women 
with gestational age of approximately 25 weeks, prenatal diagnosis of non immune hydrops fetalis 
and suspected of human parvovirus B19 infection were studied between January 1999 and December 
2005. Serology results and detection of DNA in the maternal serum, foetal serum and amniotic fluid 
confirmed that 20 pregnant women had been infected by human parvovirus B19. The ultrasound 
examination demonstrated foetal hydrops, anaemia, hepatosplenomegaly, ascites, cardiopathy and 
amniotic fluid disorders. Among the positive cases, there were three fatal losses, one by miscarriage 
and two by intrauterine foetal death.
resumo
abstract
A infecção por parvovírus humano B19 é um dos responsáveis pela hidropsia fetal. A infecção materna 
causada pelo vírus pode ser sintomática ou assintomática. Neste estudo 40 mulheres com idade gestacional de 
aproximadamente 25 semanas, diagnóstico pré-natal de hidropsia fetal e suspeita de infecção por parvovírus 
humano B19 foram avaliadas durante o período de janeiro de 1999 a dezembro de 2005. Os resultados de 
sorologia e detecção de DNA no soro materno, fetal e fluido amniótico confirmaram 20 mulheres grávidas 
com infecção por parvovírus humano B19. A análise de ultra-som demonstrou hidropsia fetal, anemia, 
hepatosplenomegalia, ascite, cardiopatia e desordens amnióticas. Entre os casos positivos, ocorreram três 
perdas fetais: uma por aborto e duas por morte fetal intra-uterina.
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Introduction
Human parvovirus B19 (HPV B19) is a small, nonenveloped 
desoxyribonucleic acid (DNA) virus that exclusively infects 
humans(4). After infection, parvovirus B19 replication occurs 
primarily in erythrocytes and erythroblasts, which can lead 
to anaemia in predisposed individuals(5, 23). Infected healthy 
adults generally have only mild constitutional symptoms. 
In contrast, fetal parvovirus B19 is a congenital disorder 
that is characterized by non-immune hydrops (IUFD), 
ascites, pleural effusion, hypertrophic cardiomyopathy, 
placentomegaly, ventriculomegaly, and other findings 
caused by transplacental transmission of parvovirus to the 
fetus(6, 12, 14). The yearly peak incidence of infection occurs 
during spring and epidemics occur every four years(23). The 
prevalence of immunoglobulin G (IgG) antibodies directed 
against B19 virus (B19V) in the population ranges from 2% 
to 15% in 1- to 5-year-old children; 15%-60% in 6- to 19-
year-old children; 30%-60% in adults and more than 85% 
in the geriatric population(12). Hutataco et al.(13), reported 
in Caieiras, São Paulo, Brazil, that seroprevalence of 72% 
was observed in adults (31-40 years). In Rio de Janeiro, 
Brazil, seroprevalence was 71.2% in pregnant women of 
up to 24 weeks of gestation and 21-30 years old; 76.4% 
in 31- to 40-year-old women; and 72.7% in women older 
than 41 years(19). The incidence of acute B19V infection in 
pregnancy is approximately 1%-2% in endemic periods, but 
in epidemic periods infection rate may rise to >10%(7, 21). The 
peak incidence of B19V-associated hydrops fetalis is between 
17 and 24 weeks of gestation(10, 12). A fetus affected by 
B19V may show signs of hydrops fetalis on ultrasound 
investigation, typically marked ascites, cardiomegaly and 
pericardial effusion. In advanced stages, generalized edema 
and a thick hydropic placenta can be found. In many cases, 
the diagnosis of foetal parvovirus B19 infection is usually 
made only after the finding of fetal hydrops. Cases of fetal 
death due to HPV B19 infection have been described mostly 
between 20 and 24 weeks of gestation, but cases of IUFD 
as early as 10 weeks and as late as 41 weeks gestation have 
also been described(3, 16). The interval between HPV B19 
infection and development of non-immune hydrops fetalis 
(NIHF) ranges from two to six weeks(2, 11, 14, 22). The rapid 
correction of anaemia by in uterus transfusion of packed 
erythrocytes largely prevents fetal death(2, 16). The infection 
by parvovirus B19 is diagnosed by the detection of IgM 
antibodies in both maternal and fetal blood, but in some 
cases, maternal anti B19-IgM can no longer be detected 
when hydrops fetalis develops. In most of the reported 
cases, DNA detection in fetal tissues is the method of choice 
for diagnosis(8). We hereby report the results of HPV B19 
detection in maternal and fetal samples from non-immune 
hydrops fetalis.
Material and methods
This was a retrospective study of 40 pregnancies with 
a median gestational age of 25 weeks and with alterations 
in their ultrasonography from to the fetal medicine unit 
at Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo (FMUSP) for possible parvovirus 
B19 exposure between 1999 and 2005 in São Paulo, Brazil. 
The patients were monitored with ultrasounds, and hydrops 
fetalis was characterized by one or more clinical signs, 
such as peripheral edema, ascites, anaemia and congestive 
heart failure. The gestational week (GW) was based on the 
last menstruation date, ultrasonographic and postnatal 
classification methods. The evaluation of possible exposure 
to parvovirus B19 (as well as specific information regarding 
the nature of the exposure) and clinical symptoms, such as 
facial rash, body rash, fever, runny nose, cough, joint pain, 
general fatigue and lymphadenopathy, were collected using 
a computerized database maintained at our institution. 
The samples were analyzed at the Adolfo Lutz Institute, 
São Paulo. In this study, the following were processed: 
40 maternal serum samples; 15 foetal cord blood and 
29 amniotic fluid samples. All mothers were subjected to 
cytogenetic analysis.
Serology
The samples were tested by a commercial enzyme-linked 
immunosorbent assay (ELISA) kit for the detectation of B19 
immunoglobulin M (IgM) antibodies using recombinant 
capsid protein VP2 as antigen (Biotrin International Ltd.).
Amplification by nested PCR
Polymerase chain reaction (PCR) assay was carried out as 
described by Durigon(9). For PCR, the oligonucleotide primers 
used were P1 (5’ AAT ACA CTG TGG TTT TAT GGG CCG 
3’) and P6 (5’ CCA TTG CTG GTT ATA ACC ACA GGT 3’), 
nucleotide sequences 1399-1422 and 1682-1659, respectively. 
For nested PCR, the oligonucleotide primers used were P2 (5’ 
CCA TTG CTG GTT ATA ACC ACA GGT 3’) and P5 (5’ CTA AAA 
ATG GCT TTT GCA GCT TCT AC 3’), nucleotide sequences 
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1498-1525 and 1600-1576, respectively. The extracted DNA 
(10 µl) was added to the PCR mixture containing 10 µl of 
10X reaction buffer (Applied Biosystems, Foster City, CA, 
USA); 200 µM each dATP, dCTP, dGTP, dTTP; 0.5 µM each 
oligonucleotide primer, and 2.5 U of Taq polymerase 
(Applied Biosystems Foster City, CA, USA). After the 
first amplification, the second (nested) PCR was carried 
out and 10 µl of the first PCR product was added to the 
nested PCR mix using the specific primers and put into in 
Applied Biosystems Thermocycler with the following cycle 
definitions: 94°C/5 minutes; 95°C/45 seconds; 55°C/1 
minute, 72°C/1.5 minute (35 repetitions after second 
step) and finally, 72°C for five minutes, obtaining a 102-
bp fragment. The amplified products were submitted to 
1.5% agarose gel electrophoresis and ethidium bromide 
staining PCR products were visualized on ethidium-stained 
agarose gel. The negative control was processed in parallel 
with water as a template.
Results
Among 40 pregnant women with diagnosis of 
hydrops fetalis, 20 cases were confirmed to be infected 
with HPV B19 by the detection of DNA in maternal and 
fetal sera and/or amniotic fluid. B19 DNA was detected 
in 19 maternal sera, 10 fetal sera and 13 amniotic fluid 
specimens. IgM antibodies to parvovirus were positive in 
15 maternal and 10 fetal sera (Table 1). The gestational 
age at the time of diagnosis of maternal among the 
women was 22 and 25 weeks (Table 1). The sources of 
the infections were unknown in all the studied cases, 
and 60% of the mothers did not report prodromal 
symptoms as sore throat, low grade fever, adenopathies 
(cervical and/or axillary) and/or malaise. The chromosome 
karyotype was a normal 46, XX. Pregnancy outcomes are 
also described in Table 1. Among the fetuses, three that 
survived were concomitantly diagnosed as fetal anaemia 
Table 1 Laboratory features in cases positive for parvovirus HPV B19
HPV B19 detection
Case number Gestational 
age
Maternal 
IgM
Serum 
DNA Fetal IgM
Serum 
DNA
Amniotic 
fluid DNA IUT
Intrauterine 
fetal death
Pregnancy 
termination
1 22 (-) (+) (+) (+) NP Not Not Yes
2 22 (-) (+) (+) (+) NP Not Not Yes
3 22 (+) (+) NP NP (+) Yes Yes Not
4 22 (+) (+) NP NP (+) Not Not Yes
5 22 (+) (+) NP NP (+) Not Not Yes
6 23 (+) (+) (+) (+) NP Not Not Yes
7 23 (-) (+) (+) (+) NP Not Yes Not
8 23 (+) (+) (+) (+) NP Yes Not Yes
9 23 (+) (+) NP NP (+) Not Not Yes
10 23 (+) (+) NP NP (+) Not Not Yes
11 24 (-) NP (+) (+) (+) Not Not Yes
12 24 (-) (+) NP NP (+) Not Not Yes
13 24 (+) (+) NP NP (+) Not Not Yes
14 24 (+) (+) (+) (+) (+) Not Not Yes
15 25 (+) (+) NP NP (+) Not Not Yes
16 25 (+) (+) (+) (+) NP Not Not Yes
17 25 (+) (+) NP NP (+) Not Yes Not
18 25 (+) (+) (+) (+) NP Not Not Yes
19 25 (+) (+) (+) (+) (+) Yes Not Yes
20 25 (+) (+) NP NP (+) Not Not Yes
NP: not performed; IUT: intrauterine transfusion.
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and intrauterine blood was supplied (Table 1). Cases 3 and 
19 received one intrauterine transfusion and in case 8, the 
fetus showed severe anaemia and three blood transfusions 
had to be carried out. Among the three fetal deaths, two 
were the aforementioned cases with hydrops and severe 
anaemia and one was a miscarriage. All three cases were 
serologically negative for the toxoplasmosis, rubella virus, 
cytomegalovirus, herpes simplex virus (TORCH) syndrome. 
The frequency of cases demonstrated a substantial 
variation during the year (Table 2).
IgM antibody detection in 55 pregnant women (32% of 
them in the first trimester, 54% in the second, and 14% in 
the third). In contrast, HPV B19 IgM and DNA were detected 
in all samples of fetal cord blood analyzed and the number 
of positive IgM in fetal samples was high when compared 
with other published data(8, 24). Using standard procedures, 
detection of HPV B19 specific IgM in fetal blood has a 
sensitivity of 29% compared to almost 100% for PCR(1, 10). 
However, low HPV B19 DNA levels may persist for years after 
acute infection and, therefore, low positive PCR results for 
HPV B19 do not prove recent infection(15).
The cases of parvovirus B19 reported in this study 
occurred in different years, and the majority of the positive 
cases occurred during the period 1999-2001. In addition, 
during the years 1999 and 2000, an outbreak of erythema 
infectiosum was identified in four states in Brazil (São Paulo, 
Paraná, Santa Catarina and Rio Grande do Sul) and was 
investigated by us at Instituto Adolfo Lutz(18). The clinical 
manifestations of HPV B19 infection in pregnant women are 
different from that in non-pregnant women. Previous reports 
have shown that 30%-60% maternal HPV B19 infection is 
entirely asymptomatic(9, 16), which is in good agreement 
with our finding of 60% asymptomatic patients. Enders(8) 
reported that there was no association between the presence 
of maternal symptoms and the incidence of non-hydropic 
fetal death or hydrops fetalis, although the presence of rash 
and/or arthropathy between 9 and 16 weeks of gestation 
was associated with an increased risk on non-hydropic fetal 
death. According to different prospective studies, the risk of 
developing hydrops fetalis varied between 0% and 12.5% 
with a maximum of 7.1% when infection occurred between 
13 and 20 gestational weeks. The overall rate of parvovirus 
B19-related fetal loss has been estimated as between 4% and 
16% with a peak frequency during the early second trimester, 
as seen in three of our cases. The mechanism involved in the 
fetal loss is explained by the tropism of HPV B19 for immature 
erythropoietic cells, a substantial increase in haemopoiesis 
at that gestational age, and low anaemia tolerance due to 
small haematological reserves(3, 10, 12). Although the replication 
of parvovirus B19 usually occurs in red blood precursors, 
recent studies have shown that this virus can also infect 
myocardial cells and thus contribute to heart failure(17). 
Between the studied cases, intrauterine transfusion of packed 
erythrocytes was made in three fetuses that developed 
cardiorespiratory insufficiency in association with severe 
anaemia. Management of B19V infection with intrauterine 
transfusion (IUT) can correct fetal anaemia and may reduce 
the mortality of B19V infection significantly. Timely IUT of 
Table 2
Cases of hydrops fetalis from 1999 to 
2005 tested for detection of human 
parvovirus B19
Year Total pos/neg Fetal abnormalities
1999 6 (3/3) All cases with hydrops, 
15 of them with anemia, 
one of them with 
hepatoesplenomegaly 
and one with 
cardiopathy
2000 8 (6/2)
2001 6 (3/3)
2002 4 (2/2)
2003 4 (2/2)
2004 6 (2/4)
2005 6 (2/4)
Discussion
Parvovirus infection is one of the leading causes of IUFD 
in neonates. Parvovirus infects the fetal liver, which is the site 
of erythrocyte production during early development leading 
to fetal anemia. The most common clinical manifestation of 
fetal anemia is hydrops, which is observed sonographically 
as skin edema, ascites, pleural effusion, placentomegaly and 
polyhydramnios(6, 14, 23). Most cases of hydrops are due to 
fetal aplastic anaemia, which leads to high-outpout cardiac 
failure and myocarditis(2, 5).
We studied the occurrence of HPV B19 infection in 
maternal and fetal samples of cases with non-immune 
hydrops fetalis. In the present study, 20 of the 40 cases were 
positive to parvovirus B19. Among the positive cases, IgM 
antibodies to parvovirus were detected in 15 maternal and 
10 fetal sera. The absence of B19 IgM in maternal blood at 
the time of B19-induced hydrops has been reported in several 
studies; in general, IgM detection rates in those studies varied 
widely: 41%(10); 45%(20); 52.9%(24) and 81.3%(8). Enders et 
al.(10) reported that acute infection was demonstrated by 
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fetuses with severe hydrops reduces the risk of fetal death(10). 
In most cases, one transfusion is sufficient for fetal recovery. 
Following successful transfusion, it may take weeks for all 
hydropic signs to disappear. A few cases of spontaneous 
resolution of hydrops due to parvovirus infection have been 
described. This has led to the discussion of the best time to 
intervene or whether to intervene at all. Only fetal blood 
sampling can provide information on fetal haemoglobin and 
reticulocyte count, and thus on whether the fetus may be in 
a spontaneous recovery phase or not. Furthermore, adequate 
monitoring by ultrasound and Doppler are necessary for 
timely recognition of possible fetal complications. In Brazil, 
because of the reduction in rubella incidence rates after the 
introduction of national mass vaccination campaigns, HPV 
B19 infection has increased in importance, particularly in 
children and pregnant women.
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